# Expanded Criteria Donor: Revisited?

Bryce Kiberd

## Overall AIM of ECD Policy

Increase organ utilization

### Objectives

- Review the definitions of ECD
- ECD allocation options
- Evidence supporting the use ECD

#### Definition of ECD

- Potential Low Function
  - Heart beating (i.e. older donor)
  - Non-heart beating (Deceased Cardiac Donor)
- Potential High Risk to Recipient
  - Infection (HCV, HBV, others)
  - Cancer (primary brain, historic cancer)
  - Bought kidneys?

### Many ECD Definitions

- United Network Organ Sharing (UNOS)
- Deceased Donor Score
- Donor Histology
- Donor Age

# UNOS criteria Risk of Graft Loss 1.7 times higher than a standard donor kidney


- >60 year old donor
- 50-60 age donor and 2 of the following 3
  - Hypertension
  - Serum Creatinine 132 µmol/L at any time
  - CVA as cause of death

Current discard rate 40% of these donors
Current utilization is 15% of all transplanted kidneys

#### Definition of Standard Donor


- Donor age 10-39
- Death Non-CVA
- No hypertension
- Terminal creatinine <132 μmol/L</p>

#### ECD vs SD Graft Survival (Ojo JASN 2001)



#### Cost Savings ECD and SD vs Dialysis

(Schnitzler Transplantation 2003)



### UNOS Implementation (Oct 2002)

- Identify willing ECD kidney recipients
- Consent potential recipients
- Minimal cold time

http://www.unos.org/downloadables/ExpandedCriteriaDonorKidneyPolicyBrochureProf10072002Final.pdf)

#### Information on Consent

- Expect increase in delayed graft function
- Expected decrease in graft survival
- Expected decrease in waiting time
- Expected increase in survival compared to waiting.
- Benefit of transplant prior to increased morbidity

Sample consent AJT 2003;3 (suppl 4):124-5


#### **UNOS Problems**

Many kidneys discarded that should be used (WTC 2006 pg 140)

	Graft Loss	Discard Rate
Donor with PVD	0.87	3.49
Urine protein	1.10	2.20
Donor age 65-69	1.19	6.98
Cysts	0.58	1.81
Resistance (pump)	1.16	5.67

 Re-evaluation of criteria (CVA death vs Hypertension/Creatinine)

## UNOS Problems Schold et al AJT 2006;6:1689



Some centers have few awaiting ECD Some centers have almost all on ECD lists


# Deceased Donor Criteria Nyberg et al AJT 2003

Donor Age 0-	-25 points
--------------	------------

ypertension	0-5
 portororr	

Total 0-39

#### Nyberg et al.



## Histologic Criteria Remuzzi et al NEJM 2006;354:343

- Donors > age 60 (recipients >50 age or difference <10 years)</li>
- 16 gauge needle (40-50 glomeruli)
- Evaluate vessels, glomeruli, tubules and interstitium
- Score 0-3 each component
- Total score (0-12)
  - >6 discard
  - 4-6 dual kidney
  - ≤3 single kidneys

#### Criteria Comparison Luis et al WTC 2006 pg 143

n=95

	Graft Survival	Creatinine		
Histologic	At I year			
• 0-3	87%	1.30± 0.44		
• 4-6	85%	$1.45 \pm 0.56$		
Deceased Donor Score				
• A	96%	$0.95 \pm 0.24$		
• B	93%	$1.55 \pm 0.44$		
• C	73%	$1.64 \pm 0.60$		

# Criteria Comparison Rossini et al WTC 2006 pg 236 n=167 transplants

#### Concordance Score

■ Histologic  $0.64 \pm 0.08$ 

■ DDS  $0.73 \pm 0.08$ 

■ Integrated  $0.81 \pm 0.08$ 

Integrated score = DDS (0-39) + 13\*Glom score (0-3) Cut point 34 (5 year GS 97% vs 67%)

# Old for Old (>64 to >64) Fritsche et al Am J Transplant. 2003;3:1434

 43% increase in transplantation of the elderly with reduced wait time (WTC 2006 pg 141)

	Old for Old	Traditional Allocation
<ul><li>R Age</li></ul>	68±3	64±3 years
• D Age	71±4	45±15 years
• CIT	$7.8 \pm 3.4$	14.2 ±5.5 h
<ul> <li>HLA MM</li> </ul>	$4.2\pm1.2$	1.6 ± 1.7
<ul> <li>PSurvival</li> </ul>	85%	89%
<ul> <li>GSurvival</li> </ul>	84%	87%

### UNOS vs Eurotransplant Cecka et al AJT (ATC 2004)

- 1500 cadaver kidneys discarded in US annually
- 37% of 61-65 y/o donor kidneys discarded in US vs 7% in ET
- 54% of >65 y/o donors kidneys discarded in US vs 8% in ET
- Eurotransplant Senior Program >65 y/o donor kidneys to >65 y/o recipients

## What should be our plan?

### Avoid "ECD"

# Rather 'Optimized Allocation'

### Optimized Matching









### Optimized Matching











# Remaining Life Years Remaining Miles to Travel

Vancouver to St John's

Gander to St John's

### **Optimized Matching**

Vancouver to St John's



Gander to St John's





# Our Current Plan 'Now Under Review'


- Retrieve All kidneys
- Visibly scarred kidneys should be discarded.
- Biopsy some deceased donors kidneys
  - > age 65
  - > age 55 and donor CrCl <70 ml/min</li>
  - Discard advanced arteriolar sclerosis or interstitial fibrosis (use 16 g needle)
- Allocate to
  - Older (>59) or diabetic
  - Avoid the sensitized
  - Minimize cold ischemic time
  - Avoid large weight or age mismatches

## Still Some Angst

**Analysis of Outcomes** 

#### Mortality Rate On Wait List


Per 100 patient years



Gill et al Kidney Int 2005

#### Transplant Rates by Time on List


Gill et al AJT 2005;5 (Suppl 11):261



#### Probability of Transplantation

Cumulative probability

Overestimated since it ignores removal from the list



# The ECD in deceased donor renal transplantation.

JAMA 2005:294:2726

- Cohort of >109,000 ESRD patients 1/95-12/02
- Compared transplanted outcomes from wait list to death for standard and ECD recipients.
- RR for mortality with ECD kidney (vs SD)
  - RR=1 Implies ECD and SD equivalent
  - RR<1 Implies ECD better than SD</li>
  - RR>1 Implies ECD worse than SD

# The ECD in deceased donor renal transplantation.

JAMA 2005:294:2726

Short Wait (<3.5 yrs) Long Wait

Age 40-59 0.90 0.71 (0.60-0.85)\*

Age 60+ 0.92 0.63 (0.50-0.78)\*

DM 0.77 (0.64-0.94)\* 0.74 (0.59-0.924)\*

# The ECD in deceased donor renal transplantation.

JAMA 2005:294:2726

- Net Benefit
  - Long waiting times
    - Diabetes mellitus and >40 years of age
  - Short waiting times
    - Diabetes mellitus

## The ECD dilemma in cadaveric renal transplantation.

**Schnitzler MA et al Transplantation 2003** 

Selected subsets revealed differences in wait times that equated QALYs for ECD and standard donors:

Average 3.2 years

African Am. 4.4 years

Age under 30 4.0 years;

Age over 60 11 months.

### Future Allocation Solutions

# Optimized Solution WTC 2006 pg 322


Recipient Score (1-4 grade based on DM, Age, IHD, Dialysis time)

#### **Deceased Donor Score**

	A	В	С	D
1	+3	-8	-13	-15
2	+20	+10	+4	+0.4
3	+24	+14	+8	+4.5
4	+27	+16	+11	+7

Graft Survival minus Patient Survival in %

# Maximizing Value Meier-Kriesche at al AJT 2005;5:1725



### **Matching Recipient and Graft Survival**

Baskin-Bey et al Transplantation 2006; 82:10

**TABLE 3.** Renal years according to age group and Deceased Donor Score

Recipient age	Recipient renal	Donor renal years				
(years)	years	A	В	C	D	
<18	10808	1126	446	68	0	
18-39	36446	6736	4206	1971	65	
40-49	25647	8290	5990	2801	120	
50-59	23950	$8173^{a}$	$8062^{a}$	5666	400	
60–69	11689	$3667^{b}$	$3802^{b}$	$3376^{b}$	$844^b$	
≥70	2117	569 <sup>c</sup>	583 <sup>c</sup>	$648^c$	31 <del>7</del> c	
Total	110656	28561 +	23090 +	14530 +	1746 = 67926	

2002 calculation of renal years = number of transplants × survival (recipient or graft). Recipient survival was substituted for the original graft survival data (see Fig. 5); in these marked areas, graft survival superceded recipient survival. Our model attempts to preclude this occurrence.

<sup>&</sup>lt;sup>a</sup> Corrected graft survival used for calculation: 13.90 years.

<sup>&</sup>lt;sup>b</sup> Corrected graft survival used for calculation: 9.70 years.

<sup>&</sup>lt;sup>c</sup> Corrected graft survival used for calculation: 7.20 years.

### **Matching Recipient and Graft Survival**

Baskin-Bev et al Transplantation 2006: 82:10

**TABLE 4.** Optimized expected renal year supply for 2002

Recipient age (years)	Deceased Donor Score	N	Median graft survival (years)	Median recipient survival (years)	Optimized renal years
<18	A	193	8.8	26.7	1698
18-39	A	1365	10.9	26.7	14879
40-49	A	782	15.1	18.9	11808
40-49	В	575	12.2	18.9	7015
50-59	В	1502	17.1	13.9	25684
50-59	C	221	11.4	13.9	2519
60-69	C	1205	13.0	9.7	11689
≥70	C	73	18.0	7.2	526
≥70	D	221	7.2	7.2	1591
Total		6137		(	77409


+10,000 Renal Years

Calculation summary: 110,656 years of renal function to meet demand in 2002; 67,926 years of renal function supplied by deceased donors in 2002 (real); 77,409 years of renal function supplied by deceased donors in 2002 (optimized data); + 9483 additional years of renal function saved by optimization; 13.96% increased by optimization; 22.19% deficit reduced by optimization.


# THE NET LIFETIME SURVIVAL BENEFIT KP McCullough et al WTC Abstract #217

- UNOS rethinking allocation of Standard Donors
  - More utility based
- For every donor kidney
  - The net gain in life expectancy is calculated
  - Cox model, years 4-10 with a Weibull model, Models included candidate age, albumin, BMI, years of ESRD, peak PRA, previous transplant, primary diagnosis, KI v. KP, and diabetes mellitus.

### THE NET LIFETIME SURVIVAL BENEFIT



## Competing Ethical Principles



## Other Organs

# ECD Liver Organs Decrease Wait List mortality WTC 2006 #603

### ECD Definition

- >14 hours of cold ischemia time
- AST>150 Na>170 Macrosteatosis >30% (Liver Transpl 2005;11:1184)
- Non-heart beating donors
- Split liver
- Hepatitis C or B donor

### **Liver Allocation**

- Recipient Scoring System
  - MELD (Model for End Stage Liver Disease)
  - PELD
- ECD Allocation (under review WTC Abstracts)
  - Avoid in Combined Kidney/Liver (#609)
  - Avoid MELD <15 (#607)</li>
  - Avoid in high risk MELD >31 (#1000)
  - Avoid intermediate MELD 15-26 (#1001)

### Conclusions

- Maximize use of donor organs
- ECD definitions and allocation will change
  - A Canadian approach is under review (Oct 26)
- Optimized Solution (rather than ECD)
  - Keep it simple
  - Size limitations
    - 65+ to 65+ versus ≥60 to ≥60 or DM)

# Having Enough Patients on the Wait List

### **Examination of the Wait List**

- <14% of adult Halifax program dialysis population on wait list
- 16% of Canada and USA

## Access to the Transplant Wait List

Am J Transplant. 2006 Sep 4; [Epub ahead of print]

Kiberd B, Boudreault J, Bhan V, Panek R.

### Aim:

 To examine policy that all patients with ESRD are considered for transplantation

### Hypotheses

- That only about 20% are referred
- That burden of comorbidity impacts on referral status
- That a proportion of patients would not be referred despite relatively low comorbidity

### Access to the Wait List

Am J Transplant. 2006 Sep 4; [Epub ahead of print]

- 113 consecutive ESRD patients from 4/05-4/06
  - 92 hemodialysis, 13 PD, 8 pre-emptive transplant
  - Age 62±15 (25-85)
  - Diabetes Mellitus 35%
  - Cancer 20%
  - CHF 34%
  - IHD 35%
  - Stroke 14%

# Access to the Wait List AJT in Press 2006

- Comorbidity Indices
  - Charlson
    - 14 weighted health states
  - ESRD
    - 12 weighted health states


## Access to the Wait List AJT in Press 2006

- 47 (42%) Referred for transplantation
- 48 (43%) Contraindication
  - Canadian Guidelines 2005 CMAJ
  - Cancer-13, CV event -15, Active Disease-20
- 26 (23%) Not referred and No contraindication

## Patients with No Contraindication

	Referred N=39	Not Referred N=26	prob
Age in years	50±12	75±7	0.000
Diabetes Mellitus	12 (31%)	13 (50%)	
Cancer	3 (7.7%)	6 (23%)	
IHD	7 (21%)	9 (35%)	
CHF	6 (12%)	11 (42%)	0.016
Albumin (g/L)	35±5	32±6	0.049
Charlson Index	3.3±1.6	5.1±2.1	0.000
ESRD index	1.4±1.8	3.3±2.5	0.001

#### **ROC Curve for Referral**



Concordance Statistic

Age 0.99 (0.97-1.00)

Charlson 0.76 (0.61-0.89)

ESRD 0.75 (0.62-0.87)

If no contraindications
Almost everyone <65 is
referred
Almost no one >70 is
referred

## Our Findings

- Higher referral rate than expected
- Are acceptable candidates being discriminated against by age?